Experience of treatment with long-acting injectable cabotegravir/rilpivirine (LA iCAB/RPV) in viremic young patients with perinatally acquired HIV with adherence challenges: A five-case series
LA iCAB/RPV appears to be a promising treatment strategy for youth with perinatally acquired HIV facing persistent adherence barriers and previous treatment failures. Further studies with larger cohorts and extended follow-up are needed to confirm these results and inform care strategies.
Authors
- Alice‐Andrée Mariaggi (ORCID: https://orcid.org/0000-0002-1677-2967)
- Clémentine de La Porte des Vaux (ORCID: https://orcid.org/0000-0002-5472-7032)
- J.-P. Viard
Institutions
- Hotel Dieu Hospital (CA)
- Hôpital Cochin (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôtel-Dieu de Paris (FR)
Publication Details
- Journal
- International Journal of Infectious Diseases
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1016/j.ijid.2025.108104
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00